ALXN, VRTX, REGN, BIIB And CELG, 5 Drugs Stocks Pushing The Industry Lower

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 63 points (0.4%) at 15,199 as of Monday, July 8, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,878 issues advancing vs. 1,083 declining with 93 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 1.0%. Top gainers within the industry include Allergan ( AGN), up 2.8%, Sanofi ( SNY), up 1.1%, Teva Pharmaceutical Industries ( TEVA), up 0.9%, AstraZeneca ( AZN), up 0.7% and GlaxoSmithKline ( GSK), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $2.39 (-2.5%) to $94.06 on average volume. Thus far, 587,254 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $94.06-$97.00 after having opened the day at $97.00 as compared to the previous trading day's close of $96.45.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.7 billion and is part of the health care sector. Shares are up 2.9% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $1.89 (-2.3%) to $80.54 on light volume. Thus far, 511,469 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $80.24-$83.25 after having opened the day at $83.25 as compared to the previous trading day's close of $82.43.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.9 billion and is part of the health care sector. Shares are up 96.7% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $6.50 (-2.8%) to $226.98 on light volume. Thus far, 407,496 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $225.78-$235.99 after having opened the day at $234.81 as compared to the previous trading day's close of $233.48.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $22.3 billion and is part of the health care sector. Shares are up 36.5% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $3.55 (-1.6%) to $218.10 on light volume. Thus far, 442,528 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $218.04-$225.22 after having opened the day at $223.38 as compared to the previous trading day's close of $221.65.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $51.6 billion and is part of the health care sector. Shares are up 48.6% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is down $0.90 (-0.7%) to $121.58 on light volume. Thus far, 1.0 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $121.46-$124.68 after having opened the day at $123.00 as compared to the previous trading day's close of $122.48.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $50.4 billion and is part of the health care sector. Shares are up 56.1% year to date as of the close of trading on Friday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Stock Futures Add to Gains After Solid November Jobs Report

Stock Futures Add to Gains After Solid November Jobs Report